Adjuvant chemotherapy compared with observation in patients with T2aN0 stage IB lung adenocarcinoma.

ABSTRACT:

Introduction

For patients with T2aN0 stage IB lung adenocarcinoma, benefits of adjuvant chemotherapy remain controversial. Here, we aimed to evaluate such benefits.

Methods

This retrospective cohort study was conducted on the database of the National Taiwan Cancer Registry. We analyzed patients with T2aN0 stage IB lung adenocarcinoma (re-classified by AJCC 8th edition) diagnosed during the period from January 2011 to December 2017. They were divided into two groups: (1) group 1: tumor <=3 cm with visceral pleural invasion (VPI); (2) group 2: tumor >3 cm, but <=4 cm. Overall survival (OS) and cancer specific survival (CSS) were evaluated. Risk factors for survival were determined.

Results

A total of 2,100 patients with T2aN0 stage IB lung adenocarcinoma (1,265 in group

SUBMITTER: Lee PH 

PROVIDER: S-EPMC10011699 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature